Clinical Trial

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Protocol Amendment History 4 changes
notable Trial sites expanded: 66 -> 75 locations 2026-05-20
notable Trial sites expanded: 55 -> 63 locations 2026-04-22
notable Trial sites expanded: 29 -> 55 locations 2026-04-14
notable Trial sites expanded: 25 -> 29 locations 2026-04-02
Trial Details
NCT Number NCT07231419
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 734 participants
Start Date 2025-11-21
Primary Completion 2027-04-06 (estimated)
Study Completion 2027-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-20